Form 8-K - Current report:
SEC Accession No. 0001193125-25-000084
Filing Date
2025-01-02
Accepted
2025-01-02 07:10:30
Documents
15
Period of Report
2025-01-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d859264d8k.htm   iXBRL 8-K 24594
2 EX-99.1 d859264dex991.htm EX-99.1 27618
6 GRAPHIC g859264g0102104044225.jpg GRAPHIC 2649
  Complete submission text file 0001193125-25-000084.txt   185422

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nmra-20250102.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20250102_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20250102_pre.xml EX-101.PRE 11264
17 EXTRACTED XBRL INSTANCE DOCUMENT d859264d8k_htm.xml XML 3639
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 25500214
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)